WO2002056003A2 - Procede et formulations pour la separation de macromolecules biologiques - Google Patents
Procede et formulations pour la separation de macromolecules biologiques Download PDFInfo
- Publication number
- WO2002056003A2 WO2002056003A2 PCT/US2002/001132 US0201132W WO02056003A2 WO 2002056003 A2 WO2002056003 A2 WO 2002056003A2 US 0201132 W US0201132 W US 0201132W WO 02056003 A2 WO02056003 A2 WO 02056003A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- matrix formulation
- lpa
- matrix
- linear polyacrylamide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 238000009472 formulation Methods 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 30
- 238000000926 separation method Methods 0.000 title abstract description 14
- 229920002521 macromolecule Polymers 0.000 title abstract description 6
- 239000011159 matrix material Substances 0.000 claims description 69
- 150000007523 nucleic acids Chemical class 0.000 claims description 50
- 108020004707 nucleic acids Proteins 0.000 claims description 43
- 102000039446 nucleic acids Human genes 0.000 claims description 43
- 229920002401 polyacrylamide Polymers 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 21
- 239000003398 denaturant Substances 0.000 claims description 16
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
- 239000004202 carbamide Substances 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 9
- 238000005251 capillar electrophoresis Methods 0.000 claims description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 abstract description 3
- 102000040430 polynucleotide Human genes 0.000 abstract description 3
- 239000002157 polynucleotide Substances 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 18
- 238000001962 electrophoresis Methods 0.000 description 17
- 239000012634 fragment Substances 0.000 description 17
- 238000007873 sieving Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000329 molecular dynamics simulation Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- 238000001818 capillary gel electrophoresis Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- -1 2-pyrrolidinone) Chemical compound 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44747—Composition of gel or of carrier mixture
Definitions
- the present invention relates generally to methods and formulations for the separation of biological macromolecules such as polynucleotides.
- Capillary electrophoresis has demonstrated its advantages over standard slab gel based electrophoretic techniques as a rapid, high-throughput and high-resolution method for separation of biological macromolecules, such as proteins, peptides and nucleic acids
- Capillary gel electrophoresis (CGE) is the CE-analog of traditional slab-gel electrophoresis and is most often used for size-based separation of biological macromolecules such as oligonucleo tides, DNA restriction fragments and proteins. The separation is performed by filling the capillary with a sieving matrix, for example, cross-linked polyacrylamide, agarose or linear polymer solutions.
- the invention is based in part on the discovery of new matrix formulations for easily resolving nucleic acids 15-90 polynucleotides in length.
- the invention features a replaceable matrix formulation consisting of 3M-8M urea, a buffer, at least one denaturant, a linear polyacrylamide (LPA) of about 2.5xl0 6 - 5.0 ⁇ l0 6 daltons (referred to herein as high MW LPA or long LPA), and a linear polyacrylamide of about 1.3xl0 5 - 2.0 10 5 daltons (referred to herein as low MW LPA or short LPA).
- LPA linear polyacrylamide
- the high MW LPA is provided in a size range of about 3.0 xlO 6 - 4.0 xlO 6 daltons.
- the low MW LPA is provided in a size range of about 1.5xl0 5 - 1.8x10 s daltons, e.g., about 1.6 xlO 5 - 1.7 xlO 5 daltons.
- the concentration of high MW LPA contained in the matrix formulation can range from about 1.0% to about 3.0% (w/w). In other embodiments, the concentration of low MW LPA contained in the matrix formulation can range from about 1.0% to about 3.0% (w/w). Each LPA concentration can be varied independently.
- the invention includes a matrix formulation having an organic denaturant.
- the organic denatuaraunt can be, e.g., pyrrolidinone (including 2-pyrrolidinone), N',N'-dimethylacetamide, and N',N'-dimethylformamide.
- concentration of organic denaturant can range from 5% to 20% (w/w).
- the invention also provides a method of detecting a nucleic acid in a population of nucleic acid molecules by providing a capillary electrophoresis device with a sieving matrix formulation that includes double-LPA matrix, an organic denaturant, and urea, and introducing a first nucleic acid into the formulation.
- the first nucleic acid is transported through the matrix formulation and detected. Transporting is preferably performed by electrophoresis, e.g., capillary electrophoresis.
- a second nucleic acid is introduced into the matrix formulation, transported through the matrix formulation and detected.
- the first nucleic acid and/or the second nucleic acid include a detectable label, e.g., a radioactive or fluorescent label.
- a "double-LPA matrix” is any sieving matrix that includes a mixture of high MW LPA and low MW LPA in addition to at least one denaturant, a buffer, and 3M-8M urea.
- the invention includes resolving nucleic acids in a population of nucleic acid molecules that includes nucleotides from at least 15 nucleotides to at least about 75 nucleotides in length.
- the separation results in a resolution per base higher than 1.0.
- the method involves introducing a second population of nucleic acid molecules into the sieving matrix formulation.
- the nucleic acids are separated using an electrophoresis device that is operated at a run voltage of between 10kV-14kV.
- the electrophoresis device is operated at a temperature ranging between 40°C and 60°C.
- the matrix formulations are used to determine the nucleotide sequence of at least a portion of at least one member of the population of nucleic acid molecules.
- FIG. 1 is an electrophoretogram showing the elution profile of rox-labeled DNA ladder through a standard, high MW LPA sieving matrix.
- FIG. 2 is an electrophoretogram showing the elution profile of rox-labeled DNA ladder through a double-LPA sieving matrix.
- FIG. 3 is an electrophoretogram showing the elution profile of rox-labeled DNA ladder through a double-LPA sieving matrix containing pyrrolidinone.
- FIG. 4 is a histogram comparing the resolution of DNA ladder peaks for three concentrations of low MW LPA added to the standard, high MW LPA matrix.
- FIG. 5 is a histogram comparing the resolution of DNA ladder peaks for three concentrations of pyrrolidinone added to sieving matrix.
- FIG. 6 is an electrophoretogram showing the elution profile of four consecutive injections of SNPs in one electrophoresis lane.
- Formulations of the invention include two linear polyacrylamide solutions, referred to herein as high MW polyacrylamide and low MW polyacrylamide, an organic denaturant, a buffer, and urea.
- High and low molecular weight formulations are known in the art.
- Long LPA formulations are discussed in, e.g., Ruiz-Martinez et al, Anal. Chem. 70:1516-27, 1998; Goetzinger et al., Electrophoresis 19:242-48, 1998, and in WOOO/28314.
- LPA can be obtained from commercial vendors such as Molecular Dynamics.
- Low MW LPA and high MW LPA are combined in proportions designed to optimize separation of a pool of nucleic acid sequences of a desired target nucleic acid of a desired size range.
- the target range is 15-100, or 20-90, or 30-75, nucleotides in length.
- the high MW LPA is a molecular weight of about 2.5x10 6 -
- the high MW LPA is provided in a size range of about 3.0 x 10 6 - 4.0 x 10 6 daltons.
- the low MW LPA is provided in a size range of about 1.5xl0 5 - 1.8xl0 5 daltons, e.g., about 1.6 xlO 5 - 1.7 xlO 5 daltons.
- suitable formulations include those that include low MW LPA at 1-3% w/w and high MW LPA at 1-3% w/w.
- the formulations preferably includes an organic denaturants in order to maximize high resolution and enhanced denaturation of single stranded DNA fragments.
- the organic denaturant can include, e.g., (i) 2-pyrrolidinone, (ii) N',N'-dimethylformamide, and (iii)
- N',N'-dimethylacetamide at 5-40% (w/w).
- the formulations can also include 3M-8 M urea, with a suitable buffer. Preferred concentrations of urea are 6M-7M. Buffers typically used for LPA formulations systems can be used, so long as they allow for resolution of molecules in a desired size range.
- An example of a suitable buffer 0.1-300 mM TAPS-Tris-EDTA.
- the formulations described herein can be used in any application for which resolution of small nucleic acid fragments is desired.
- the formulations can be used in, e.g., sizing a nucleic acid of interest, fingerprinting (including dideoxyfingerprinting), identification of short tandem repeats (STRs), detection of single nucleotide polymorphisms (SNPs), detection of cDNA copies of RNA molecules (include applications for detecting levels of one or more RNA sequences in a population of interest).
- the formulations are used to resolve nucleic acids that have been analyzed with single base extension (SBE) chemistry with fluorescent labeled di- deoxynucleotides.
- SBE single base extension
- Suitable primer lengths to use for single base extension is 20 to 40 nucleotides.
- SBE chemistry a nucleotide fragment (-200 bases) near the polymorphic region of the DNA is amplified using polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- Shrimp alkaline phosphatase and E. coli exonuclease I are added to the reaction mixture to digest the remaining dNTP's and PCR primers. After digestion, the sample is heated to 95 °C to destroy the remaining enzymes and the single base extension reaction is performed using fluorescent labeled di-deoxynucleotides.
- allele-specific ddNTPs are dye-labeled, a different dye for each allele.
- a primer is added that will anneal adjacent to the single nucleotide polymorphism (SNP).
- SNP single nucleotide polymorphism
- unincorporated ddNTPs are removed (e.g., using chromatographic separation such as SEPHADEXTM filtration).
- Figure 1 shows the electrophoresis run of rox-labeled DNA ladder, containing fragments of 15bp, 16bp, 17bp, 20bp, 21bp, 25bp, 32bp, 33bp, 41bp, 42bp, and 43bp.
- the sieving matrix formulation for this electrophoresis run was a standard, linear polyacrylamide ("LPA") obtained from Molecular Dynamics (also referred to herein as high MW LPA or long LPA). Individual peaks corresponding to the various fragments could not be resolved using these formulations.
- LPA linear polyacrylamide
- Double-LPA matrixes Nine different matrix formulations that included two types of linear polyacrylamide (“double-LPA matrixes”) were prepared to evaluate the separation of short nucleotide fragments.
- Each matrix formulation contained 2% of a first linear polyacrylamide solution with an average molecular weight range of 2.5x10° to 5.0x10° daltons and 7M Urea.
- the formulations additionally included varying amounts of a second linear polyacrylamide solution with an average molecular weight of about l. ⁇ xlO 5 daltons (also referred to herein as low molecule weight or short LPA), and varying amounts of the denaturant pyrrolidinone were added as shown in Table 1.
- FIG. 2 shows the electrophoresis run of rox-labeled DNA ladder, containing fragments of 15bp, 16bp, 17bp, 20bp, 21bp, 25bp, 32bp, 33bp, 41bp, 42bp, and 43bp.
- the sieving matrix formulation was 2% high MW LPA, 1.5% low MW LPA, and 7M urea. No pyrrolidinone was present.
- FIG. 3 shows the electrophoresis run of rox-labeled DNA ladder, containing fragments of 15bp, 16bp, 17bp, 20bp, 21bp, 25bp, 32bp, 33bp, 41bp, 42bp, and 43bp.
- the sieving matrix formulation for this electrophoresis separation included 2% high MW LPA, 2.5% low MW LPA, 7M urea and 5% pyrrolidinone.
- the addition of pyrrolidinone retarded the migration of the nucleotide fragments.
- Example 3 Effect of varying the amount of low MW LPA in a double-LPA matrix
- FIG. 4 presents shows a comparison of resolution for selected DNA ladder peaks for different concentrations of low MW LPA added to the standard, high MW LPA matrix.
- Matrix 2 1.5% added low MW LPA
- matrix 5 2.0% added low MW LPA
- matrix 8 2.5%o added low MW LPA. Addition of low MW LPA to 2.5% provides even resolution across the DNA size range from 21bp to 41bp.
- Example 4 Effect of varying the amount of pyrrolidinone in a double-LPA matrix
- FIG. 5 shows a comparison of resolution for selected DNA ladder peaks for different concentrations of pyrrolidinone added to sieving matrix.
- Each nucleic acid was separated in a matrix that included 5% added pyrrolidinone (Matrix 7), 10%> added pyrrolidinone (Matrix 8), or 15%) added pyrrolidinone (Matrix 9).
- the results for matrix tested are presented as Matrix 7-Matrix 8-Matrix-9 (left to right).
- the double-LPA matrix formulation provides single base resolution down to 15bp. This allows for a large increase in genotyping throughput by multiplexing several SNPs together, each of different primer length. Multiplexing can also be accomplished through multiple injections during a single electrophoresis run.
- the double-LPA sieving matrix provides improved resolution of short nucleotide fragments coupled with short run times, allowing for a greater number of injections to be multiplexed.
- FIG. 6 An application of multiplexing using double-LPA formulations is illustrated in FIG. 6. This figure presents the results of introducing four separate nucleic acids into a single matrix. No loss of resolution was observed. Additional peaks observed in the figure are due to unincorporated ddNPTs.
- FIG. 6 further shows that multiple injections can be performed in one lane of electrophoresis.
- the inserted table in Figure 6 illustrates that for the separation of these small DNA fragments the resolution is preserved even with the use of multiple injections.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002234252A AU2002234252A1 (en) | 2001-01-12 | 2002-01-14 | Method and formulations for the separation of biological macromolecules |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26148901P | 2001-01-12 | 2001-01-12 | |
US60/261,489 | 2001-01-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002056003A2 true WO2002056003A2 (fr) | 2002-07-18 |
WO2002056003A3 WO2002056003A3 (fr) | 2003-05-15 |
Family
ID=22993523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/001132 WO2002056003A2 (fr) | 2001-01-12 | 2002-01-14 | Procede et formulations pour la separation de macromolecules biologiques |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002234252A1 (fr) |
WO (1) | WO2002056003A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004020991A1 (fr) * | 2002-09-02 | 2004-03-11 | Proteome Systems Intellectual Property Pty Ltd | Gel d'electrophorese presentant des proprietes de gonflement ameliorees |
EP2362212A3 (fr) * | 2009-03-18 | 2012-03-28 | Agilent Technologies, Inc. | PDMA et cellulose dérivée en tant que support de séparation pour ADN |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6554985B2 (en) * | 1998-11-10 | 2003-04-29 | Curagen Corporation | Methods and formulations for the separation of biological macromolecules |
-
2002
- 2002-01-14 AU AU2002234252A patent/AU2002234252A1/en not_active Abandoned
- 2002-01-14 WO PCT/US2002/001132 patent/WO2002056003A2/fr not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004020991A1 (fr) * | 2002-09-02 | 2004-03-11 | Proteome Systems Intellectual Property Pty Ltd | Gel d'electrophorese presentant des proprietes de gonflement ameliorees |
EP2362212A3 (fr) * | 2009-03-18 | 2012-03-28 | Agilent Technologies, Inc. | PDMA et cellulose dérivée en tant que support de séparation pour ADN |
Also Published As
Publication number | Publication date |
---|---|
WO2002056003A3 (fr) | 2003-05-15 |
AU2002234252A1 (en) | 2002-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0854937B9 (fr) | Procedes et kit d'analyse par hybridation faisant appel a des sondes d'acides nucleiques peptidiques | |
Oberacher et al. | Analysis of polymerase chain reaction products by on-line liquid chromatography− mass spectrometry for genotyping of polymorphic short tandem repeat loci | |
Myers et al. | Nearly all single base substitutions in DNA fragments joined to a GC-clamp can be detected by denaturing gradient gel electrophoresis | |
Carey et al. | Trends in DNA forensic analysis | |
Wang et al. | A new electrophoresis technique to separate microsatellite alleles | |
AU760236B2 (en) | Denaturing gradient affinity electrophoresis and methods of use thereof | |
Guttman et al. | Separation of DNA by capillary electrophoresis | |
EP0466479B1 (fr) | Standard interne pour des séparations électrophorétiques | |
Cheng et al. | Polymerase chain reaction heteroduplex polymorphism analysis by entangled solution capillary electrophoresis | |
Kaczanowski et al. | Multitemperature single‐strand conformation polymorphism | |
Puers et al. | Allelic ladder characterization of the short tandem repeat polymorphism located in the 5′ flanking region to the human coagulation factor XIII A subunit gene | |
US5714326A (en) | Method for the multiplexed preparation of nucleic acid molecular weight markers and resultant products | |
Richards et al. | Quantitative analysis of gene expression by reverse transcription polymerase chain reaction and capillary electrophoresis with laser-induced fluorescence detection | |
Smith et al. | Capillary electrophoresis of DNA | |
EP0994968A1 (fr) | Caracterisation de l'acide nucleique | |
Mitchelson | Overview: the application of capillary electrophoresis for DNA polymorphism analysis | |
WO2002056003A2 (fr) | Procede et formulations pour la separation de macromolecules biologiques | |
Cantàfora et al. | Rapid sizing of microsatellite alleles by gel electrophoresis on microfabricated channels: application to the D19S394 tetranucleotide repeat for cosegregation study of familial hypercholesterolemia | |
Roche et al. | Capillary electrophoresis in biotechnology | |
Righetti et al. | Recent advances in capillary electrophoresis of DNA fragments and PCR products | |
Oberacher et al. | Forensic DNA fingerprinting by liquid chromatography-electrospray ionization mass spectrometry | |
CA2331742A1 (fr) | Procedes servant a quantifier de bas niveaux de modifications de sequences de nucleotides | |
Bjørheim et al. | Melting gel techniques in single nucleotide polymorphism and mutation detection: From theory to automation | |
Lorente et al. | Composite PAGE: an alternate method for increased separation of amplified short tandem repeat alleles | |
Dunsmoor et al. | Microchip electrophoresis: an emerging technology for molecular diagnostics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |